Reported Saturday, Cullinan Therapeutics Announced Initial Data From Pivotal Phase 2b REZILIENT1 Study Of Zipalertinib
Reported Saturday, Cullinan Therapeutics Announced Initial Data From Pivotal Phase 2b REZILIENT1 Study Of Zipalertinib
Cullinan Therapeutics 週六公佈了該公司 Zipalertinib 關鍵性 2b 階段 REZILIENT1 研究的初始數據。
As of a January 12, 2024 data cut-off, 31 patients had been enrolled. Patients had received a median of three prior systemic anti-cancer regimens, including prior platinum-based chemotherapy, prior anti-PD1/L1 therapy, and prior epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) therapy.
截至2024年1月12日的數據截止日，共有31名患者入組。患者已接受中位數爲三個先前的系統性抗癌療法，包括先前的鉑類化療、先前的抗PD1 / L1療法和先前的表皮生長因子受體（EGFR）酪氨酸激酶抑制劑（TKI）療法。
At data cut-off, 18 patients were evaluable for response and showed similar anti-tumor activity compared with those post prior chemotherapy in the previously reported Phase 1/2a part of the study.
在數據截至日期時，共有18名患者可用於反應評估，並顯示出與前文報道的Phase 1/2a研究中先前化療後相似的抗腫瘤活性。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。